Drugs Targeting NTRK
- Vitrakvi (larotrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.
- Rozlytrek (entrectinib) – approved for stage 4 NSCLC patients with a fusion in NTRK as detected by a biomarker test.